Roivant Social Ventures announces it is joining efforts with No Patient Left Behind to improve drug affordability and access while supporting ongoing medical innovation, through a six-figure legacy donation.
Roivant Social Ventures (RSV) is a 501(c)(3) public charity and social impact organization that partners with innovative companies, institutes, and organizations to promote systemic, sustained improvements to the way health care is accessed and delivered. The organization launched with the vision of a world where every person is born with the right and ability to access medicine and medical care, regardless of their geographic location, wealth, or insurance status. In striving for this goal, RSV spent the last six years building out programing to increase access to therapeutics for underserved people, while working to embed these principles throughout the biotechnology and healthcare industries.
In this next chapter, RSV closes out its own institutional work, while putting full support behind No Patient Left Behind (NPLB) to enhance organizational mission fulfillment, operational efficiency, and community impact.
Lindsay Androski, RSV Founder and Board President, shared, "I am immensely proud of RSV's work incubating and investing in early-stage companies and launching and expanding educational and fellowship opportunities for future equity-minded industry leaders. We also co-founded groups working to bring new therapies to underserved patient populations, such as the Global Gene Therapy Initiative and the Catalyzing Access to Research and Equity in Representation Group, and are excited to see those organizations continue their important work.
I am grateful to Roivant Sciences for enthusiastically supporting the launch of Roivant Social Ventures six years ago and our projects since that time. I can think of no better organization to carry on our legacy than NPLB.”
Ms. Androski has joined the board of NPLB.
NPLB is a network of biotechnology innovators, investors, economists, healthcare professionals, and patients working together to support solutions that improve affordability while preserving the innovation ecosystem we all rely on. NPLB's work educates stakeholders and policymakers about balanced policy solutions that enable every patient to afford the drugs prescribed by their doctor at low or no out-of-pocket cost — while also preserving the incentives for investment that spur the development of new, life-saving treatments.
NPLB's goals are to:
Eliminate out-of-pocket costs
Preserve and expedite development of the cures we still need
Ensure drugs go generic on time
Inspire all countries to appreciate the value of medicines and contribute their fair share to incentivizing innovation
You can learn more about NPLB’s work, including its free Biotech Fellowship program, through visiting their website: https://www.nopatientleftbehind.org/
RSV would like to extend a heartfelt thank you to all of those who have supported the organization’s important work in healthcare equity and access over the past six years.